	New content
American Journal of Rhinology & Allergy

Restricted access

Research article

First published online April 23, 2018

Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease

Kristen M. Walters, MD [email protected], Jeremy D. Waldram, MD, Katharine M. Woessner, MD, and Andrew A. White, MDView all authors and affiliations

Volume 32, Issue 4

https://doi.org/10.1177/1945892418770260

Abstract

Background

Aspirin-exacerbated respiratory disease (AERD), also known as Samter’s triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis. ASA desensitization with daily ASA therapy is a uniquely beneficial treatment for this disease entity and has been shown to have a significant impact on symptom scores, polyp disease, and need for systemic corticosteroids. However, no long-term studies have demonstrated whether or not ASA therapy remains safe and beneficial for these patients beyond 5–10 years.

Objective

This study was designed to determine the clinical course of AERD patients desensitized between 1995 and 2010.

Methods

A 20-question survey was distributed to patients who successfully completed ASA desensitization between January 1995 and April 2010. The questions were designed to assess ASA safety and longitudinal effects of ASA therapy in AERD.

Results

Of the 285 patients contacted, 92 (32%) completed the questionnaire. Average length of follow-up was 15 years. Of survey responders, 35 patients had discontinued ASA therapy. Although adverse reactions occurred, many also discontinued due to lack of efficacy or need for surgery. For those remaining on ASA (62%), significant improvement in sense of smell, asthma, sinus, and allergic rhinitis scores were noted (P ≤ .001). The majority of ASA patients (68%) had a positive response to treatment and did not require further sinus surgery. However, ASA therapy did not delay the time to next sinus/polyp surgery (P = .27) or reduce total number of sinus surgeries (P = .56) compared to those who stopped treatment. Nearly 85% of AERD patients on ASA therapy found it to be helpful in improving airway disease and quality of life.

Conclusion

Aspirin desensitization followed by daily maintenance ASA therapy appears to be safe and effective even after 10+ years of continuous use.

Get full access to this article

View all access and purchase options for this article.

Get Access

References

1. Samter M, Beers RF Jr. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968; 68:975–983.

Abstract

Background

Objective

Methods

Results

Conclusion

Get full access to this article

References

Cite article

Cite article

Download to reference manager

Share

Share this article

Share with email

Share on social media

Share access to this article

Information

Published In

Keywords

Rights and permissions

Authors

Affiliations

Notes

Metrics

Journals metrics

Article usage*

Articles citing this one

Figures & Media

Tables

Get access

Access options

Sign in

View options

PDF/ePub

Full Text

Also from Sage

Article usage^*